February 14, 2018 / 9:17 AM / 2 months ago

BRIEF-SanBio and Teijin to terminate licensing agreement regarding SB623 for stroke treatment

Reuters Staff

1 Min Read

Feb 14 (Reuters) - SanBio Co Ltd

* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan

Source text in Japanese: goo.gl/1xt25t

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.